The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
Year: 2024
Type: review
Source: Nature Reviews Drug Discovery
Authors: Anneliene H. Jonker, Elena-Alexandra Tataru, Holm Graessner, David Dimmock, Adam Jaffe, Gareth Baynam, James Davies, Shruti Mitkus, Oxana Iliach, Rich Horgan, Erika F. Augustine, Alison Bateman-House, Anna Maria Gerdina Pasmooij, Tim Yu, Matthis Synofzik, Julie Douville, Larissa Lapteva, Philip John Brooks, Daniel O’Connor, Annemieke Aartsma-Rus
Institutions: University of Twente, Inserm, Universitätsklinikum Tübingen, UNSW Sydney, The Kids Research Institute Australia, The University of Western Australia, Princess Margaret Hospital for Children, Perth Children's Hospital, The University of Notre Dame Australia, University of Oxford, NIHR Oxford Biomedical Research Centre, MRC Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, Canadian Organization for Rare Disorders, Kennedy Krieger Institute, New York University, Utrecht University, Medicines Evaluation Board, Boston Children's Hospital, German Center for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, United States Food and Drug Administration, National Institutes of Health, National Center for Advancing Translational Sciences, National Institutes of Health Clinical Center, Association of the British Pharmaceutical Industry, Leiden University Medical Center
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Medical Research Council
OpenAlex ID: W4404038356